Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...

Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people on Medicare and those who can no longer access compounded tirzepatide.

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

A new study has shown that two drugs - lecanemab and donanemab - could help patients stay independently by approximately 10–13 months in the early stage of Alzheimer's disease.

Lilly plans to build four new pharmaceutical plants in the US, creating 13,000 jobs and bringing its recent domestic ...

Eli Lilly is airing an ad during the Academy Awards urging customers to adopt a health skepticism when marketed drug brands that are not FDA-approved.